Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B

Clinical management, consisting of regular monitoring, and for a minority of people pharmaceutical treatment, reduces hepatitis B disease progression.

Of all people with hepatitis B in Australia, only 13 per cent are clinically managed and of the 5 per cent that do receive pharmaceutical treatment, 20 per cent do not regularly take their medication.